Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution.

ABSTRACT:

Background and objective

Approximately 20% of the global population has a Lp(a) concentrations above 50 mg/dL (> 125nmol/L), yet many remain unaware of the associated cardiovascular risks. In Mexico, routine measurement of Lp(a) is uncommon. This study aimed to investigate the frequency of Lp(a) testing, and the clinical actions taken by physicians upon detecting elevated Lp(a) concentrations in patients at a tertiary medical institution.

Methods

Using an algorithm-based screening system, we reviewed the clinical and biochemical data of patients with Lp(a) measurements from 2019 to 2024. Data were retrieved from the laboratory information system and electronic health records. Complementary assessment data were obtained from the radiology and cardiology departments.

Result

SUBMITTER: Cruz-Bautista I 

PROVIDER: S-EPMC12107857 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature